Covid19
Conditions
Brief summary
The COVID-SRLF study will evaluate the sanitary safety of the French Intensive Care Society (FICS) annual meeting held in Paris Congress Center from June 9th to June 11th 2021 in the Coronavirus Disease 2019 (COVID-2019) pandemic situation. The primary objective is to determine the proportion of attendees with a positive antigenic COVID-19 screening test at day 7 (+/- 1) of their participation to the meeting. This rate will be compared to a cohort of health care professionals (medical doctors and paramedical professionals) from the same hospital ward as the attendees but who did not attend the meeting (stratified on centers, gender, age (\< and \>= 40 years, vaccination status (0, 1 or 2 doses) and socio-professional status (medical doctor, nurse, nurse assistant).
Interventions
OTHERExposure to the FICS annual meeting (June 9-11 2021, Paris Congress Center)
The study will compare COVID-19 screening nasal antigenic self-test (Boiron Auto Test Covid Nasal) positivity at D7 and COVID-19 symptoms in the 21 days between participants to the FICS annual meeting held in June 9-11 2021 in the Paris Congress Center (conference attendees / exposed) and healthcare professionals who did not attend the meeting (controls / not exposed).
Sponsors
French Society for Intensive Care
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Healthcare professional healthy volunteer * Absence of COVID-19 symptoms in the 2 weeks prior to inclusion * Not being a COVID-19 contact case in the 2 weeks prior to inclusion * Participation to at least one day of the FICS annual meeting (June 9-11 2021)
Exclusion criteria
* Non-healthcare professional (exhibitors, congress center employees) * Refusal to participate to the study * Person under legal protection * Absence of social security affiliation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Conference attendees COVID-19 prevalence at D7 | Day 7 of the last day of the meeting (June 18th, 2021) | Proportion of conference attendees with a positive COVID-19 autotest at day 7 of the last day of the meeting (June 18th, 2021). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Controls COVID-19 prevalence at D7 | Day 7 of the last day of the meeting (June 18th, 2021) | Proportion of controls (healthcare professional not participating to the conference) with a positive COVID-19 autotest at day 7 of the last day of the meeting (June 18th, 2021). |
| Proportion of conference attendees with COVID-19 symptoms at D21 | Day 21 of the last day of the congress (July 2, 2021) | Proportion of conference attendees reporting COVID-19 compatible symptoms until day 21 of the last day of the congress (July 2, 2021). |
| Proportion of conference attendees with COVID-19-related medical consultation at D21 | Day 21 of the last day of the congress (July 2, 2021) | Proportion of conference attendees reporting COVID-19-related medical consultation until day 21 of the last day of the congress (July 2, 2021). |
| Proportion of conference attendees with COVID-19-related emergency department visit at D21 | Day 21 of the last day of the congress (July 2, 2021) | Proportion of conference attendees reporting COVID-19-related emergency department visit until day 21 of the last day of the congress (July 2, 2021). |
| Proportion of conference attendees with COVID-19-related hospitalisation at D21 | Day 21 of the last day of the congress (July 2, 2021) | Proportion of conference attendees reporting COVID-19-related hospitalisation until day 21 of the last day of the congress (July 2, 2021). |
Countries
France
Outcome results
None listed